Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:ACLX NASDAQ:AKRO NASDAQ:COLL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$23.53-1.3%$22.18$13.40▼$25.23$3.99B0.71.63 million shs1.75 million shsACLXArcellx$71.14-0.4%$66.67$47.86▼$107.37$3.93B0.28404,218 shs330,989 shsAKROAkero Therapeutics$48.37-1.0%$52.04$21.34▼$58.40$3.89B-0.28872,309 shs867,371 shsCOLLCollegium Pharmaceutical$30.07+0.7%$30.48$23.23▼$42.29$959.46M0.68267,959 shs445,406 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals-1.26%+1.20%+10.78%+57.81%+23.71%ACLXArcellx-0.35%-0.24%+7.24%+8.53%+15.09%AKROAkero Therapeutics-0.98%-4.33%-6.77%+7.80%+80.96%COLLCollegium Pharmaceutical+0.70%-5.38%-1.44%+8.75%-22.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals4.0001 of 5 stars3.43.00.00.02.54.22.5ACLXArcellx2.6029 of 5 stars3.52.00.00.03.42.50.0AKROAkero Therapeutics3.9641 of 5 stars3.53.00.04.72.90.80.0COLLCollegium Pharmaceutical4.0314 of 5 stars3.41.00.03.02.50.82.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.71Moderate Buy$28.1319.53% UpsideACLXArcellx 3.07Buy$114.3160.68% UpsideAKROAkero Therapeutics 3.00Buy$82.5070.56% UpsideCOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7545.49% UpsideCurrent Analyst Ratings BreakdownLatest COLL, AKRO, ACLX, and ACAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.007/24/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $34.006/26/2025ACADACADIA PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.006/26/2025ACADACADIA PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$37.006/26/2025ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/26/2025ACADACADIA PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.006/23/2025ACADACADIA PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.006/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/6/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.006/5/2025ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M4.11$0.70 per share33.81$4.40 per share5.35ACLXArcellx$107.94M36.32N/AN/A$8.41 per share8.46AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACOLLCollegium Pharmaceutical$631.45M1.53$12.43 per share2.42$7.10 per share4.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3717.1830.966.6322.97%17.46%10.75%8/6/2025 (Estimated)ACLXArcellx-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)COLLCollegium Pharmaceutical$69.19M$1.2224.655.00N/A6.61%99.08%15.14%8/7/2025 (Estimated)Latest COLL, AKRO, ACLX, and ACAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACLXArcellx-$1.03N/AN/AN/AN/AN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.95N/AN/AN/AN/AN/A8/7/2025Q2 2025COLLCollegium Pharmaceutical$1.88N/AN/AN/A$182.26 millionN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$263.07 millionN/A5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/7/2025Q1 2025ACADACADIA Pharmaceuticals$0.10$0.11+$0.01$0.11$239.32 million$244.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.882.80ACLXArcellxN/A4.934.93AKROAkero Therapeutics0.0316.8016.80COLLCollegium Pharmaceutical3.301.081.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%ACLXArcellx96.03%AKROAkero TherapeuticsN/ACOLLCollegium PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%ACLXArcellx8.35%AKROAkero Therapeutics7.07%COLLCollegium Pharmaceutical2.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510167.36 million123.01 millionOptionableACLXArcellx8055.11 million50.51 millionOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableCOLL, AKRO, ACLX, and ACAD HeadlinesRecent News About These CompaniesCollegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards?July 31 at 11:57 PM | finance.yahoo.comPediatrician Shares a Broad Approach to Managing ADHD in StudentsJuly 31 at 4:49 AM | yahoo.comCollegium Pharmaceutical (COLL) Projected to Post Earnings on ThursdayJuly 31 at 2:35 AM | marketbeat.comExpert tips on helping kids with ADHD transition smoothly back to school routinesJuly 29, 2025 | okcfox.comO3 Reasons to Avoid COLL and 1 Stock to Buy InsteadJuly 29, 2025 | finance.yahoo.comPacer Advisors Inc. Sells 1,723,415 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)July 27, 2025 | marketbeat.comRoyce & Associates LP Has $9.03 Million Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)July 26, 2025 | marketbeat.comWall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High?July 25, 2025 | zacks.comAre Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?July 25, 2025 | zacks.comCollegium to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.comVictory Capital Management Inc. Sells 60,823 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)July 24, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Bank of New York Mellon CorpJuly 23, 2025 | marketbeat.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Holdings Decreased by Segall Bryant & Hamill LLCJuly 20, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Buys 109,655 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)July 19, 2025 | marketbeat.comUnpacking Q1 Earnings: Organon (NYSE:OGN) In The Context Of Other Branded Pharmaceuticals StocksJuly 18, 2025 | msn.comCollegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Holdings Boosted by Emerald Advisers LLCJuly 13, 2025 | marketbeat.com8,180 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by Allspring Global Investments Holdings LLCJuly 12, 2025 | marketbeat.com5 Hot Stocks With Summer Buybacks You Can Cash In On (COLL)...July 10, 2025 | marketbeat.comCollegium Pharmaceutical Breaks Above 200-Day Moving Average - NasdaqJuly 8, 2025 | nasdaq.comCollegium Pharma Launches Up To $150 Mln Buyback Program; Stock Up In Pre-market - NasdaqJuly 8, 2025 | nasdaq.comCollegium Pharmaceutical (NASDAQ:COLL) Board of Directors Authorizes Share Buyback PlanJuly 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonD-Wave, SuperQ, and Verge: A New Path Forward for Quantum?By Nathan Reiff | July 28, 2025View D-Wave, SuperQ, and Verge: A New Path Forward for Quantum?Conagra at Rock Bottom: 7% Yield & Turnaround PoisedBy Thomas Hughes | July 13, 2025View Conagra at Rock Bottom: 7% Yield & Turnaround Poised5 Hot Stocks With Summer Buybacks You Can Cash In OnBy Thomas Hughes | July 10, 2025View 5 Hot Stocks With Summer Buybacks You Can Cash In OnCOLL, AKRO, ACLX, and ACAD Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$23.53 -0.30 (-1.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$23.17 -0.36 (-1.53%) As of 08/1/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Arcellx NASDAQ:ACLX$71.14 -0.25 (-0.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$71.08 -0.06 (-0.08%) As of 08/1/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$48.37 -0.48 (-0.98%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$48.32 -0.05 (-0.10%) As of 08/1/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Collegium Pharmaceutical NASDAQ:COLL$30.07 +0.21 (+0.70%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$30.07 0.00 (0.00%) As of 08/1/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
